Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;25(1):26-37.
doi: 10.2174/0115680096278978240204162353.

DNA Methylation-Based Diagnosis and Treatment of Breast Cancer

Xintong Peng  1 , Jingfan Zheng  1 , Tianzi Liu  1 , Ziwen Zhou  1 , Chen Song  1 , Danyan Zhang  1 , Xinlong Zhang  1 , Yan Huang  2
Affiliations
Review

DNA Methylation-Based Diagnosis and Treatment of Breast Cancer

Xintong Peng et al. Curr Cancer Drug Targets. 2025.

Abstract

DNA methylation is a key epigenetic modifier involved in tumor formation, invasion, and metastasis. The development of breast cancer is a complex process, and many studies have now confirmed the involvement of DNA methylation in breast cancer. Moreover, the number of genes identified as aberrantly methylated in breast cancer is rapidly increasing, and the accumulation of epigenetic alterations becomes a chronic factor in the development of breast cancer. The combined effects of external environmental factors and the internal tumor microenvironment promote epigenetic alterations that drive tumorigenesis. This article focuses on the relevance of DNA methylation to breast cancer, describing the role of detecting DNA methylation in the early diagnosis, prediction, progression, metastasis, treatment, and prognosis of breast cancer, as well as recent advances. The reversibility of DNA methylation is utilized to target specific methylation aberrant promoters as well as related enzymes, from early prevention to late targeted therapy, to understand the journey of DNA methylation in breast cancer with a more comprehensive perspective. Meanwhile, methylation inhibitors in combination with other therapies have a wide range of prospects, providing hope to drug-resistant breast cancer patients.

Keywords: DNA methylation; Epigenetics; breast cancer; prognosis; treatment.; triple-negative breast cancer.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Thakur C.; Qiu Y.; Fu Y.; Bi Z.; Zhang W.; Ji H.; Chen F.; Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. Front Oncol 2022,12,971288 - DOI - PubMed
    1. Park M.; Kim D.; Ko S.; Kim A.; Mo K.; Yoon H.; Breast cancer metastasis: Mechanisms and therapeutic implications. Int J Mol Sci 2022,23(12),6806 - DOI - PubMed
    1. Huo Q.; Wang J.; Xie N.; High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis. BMC Cancer 2023,23(1),501 - DOI - PubMed
    1. Loyfer N.; Magenheim J.; Peretz A.; Cann G.; Bredno J.; Klochendler A.; Fox-Fisher I.; Shabi-Porat S.; Hecht M.; Pelet T.; Moss J.; Drawshy Z.; Amini H.; Moradi P.; Nagaraju S.; Bauman D.; Shveiky D.; Porat S.; Dior U.; Rivkin G.; Or O.; Hirshoren N.; Carmon E.; Pikarsky A.; Khalaileh A.; Zamir G.; Grinbaum R.; Abu Gazala M.; Mizrahi I.; Shussman N.; Korach A.; Wald O.; Izhar U.; Erez E.; Yutkin V.; Samet Y.; Rotnemer Golinkin D.; Spalding K.L.; Druid H.; Arner P.; Shapiro A.M.J.; Grompe M.; Aravanis A.; Venn O.; Jamshidi A.; Shemer R.; Dor Y.; Glaser B.; Kaplan T.; A DNA methylation atlas of normal human cell types. Nature 2023,613(7943),355-364 - DOI - PubMed
    1. Saviana M.; Le P.; Micalo L.; Del Valle-Morales D.; Romano G.; Acunzo M.; Li H.; Nana-Sinkam P.; Crosstalk between miRNAs and DNA methylation in Cancer. Genes 2023,14(5),1075 - DOI - PubMed

Substances

LinkOut - more resources